Comparative Pharmacology
Head-to-head clinical analysis: TECENTRIQ HYBREZA versus TRISENOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TECENTRIQ HYBREZA versus TRISENOX.
TECENTRIQ HYBREZA vs TRISENOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Programmed death-ligand 1 (PD-L1) blocking antibody that binds to PD-L1, preventing interaction with PD-1 and B7.1, thereby reactivating antitumor immune responses.
Arsenic trioxide induces apoptosis in acute promyelocytic leukemia (APL) cells by targeting the PML-RARα fusion protein, leading to its degradation and subsequent differentiation and apoptosis. It also generates reactive oxygen species, disrupts mitochondrial function, and activates caspases.
840 mg intravenously every 2 weeks, or 1200 mg intravenously every 3 weeks, or 1680 mg intravenously every 4 weeks.
0.15 mg/kg IV daily until bone marrow remission, then 0.15 mg/kg IV 5 days/week for 2 weeks with 2 weeks off for up to 6 cycles.
None Documented
None Documented
Terminal elimination half-life is approximately 6.5 days (range 4–9 days), supporting a subcutaneous dosing interval of every 3 weeks.
Terminal elimination half-life for inorganic arsenic is approximately 10-14 hours, with a mean of 12 hours. The methylated metabolites have longer half-lives, contributing to accumulation with repeated dosing. Clinical context: Supports daily dosing schedule with monitoring for toxicity.
Almost entirely renal as unchanged drug (approximately 90% of a subcutaneously administered dose is eliminated via the kidneys within 96 hours). Biliary/fecal elimination accounts for less than 1%.
Primarily renal excretion of unchanged arsenic (approximately 15-30% of the dose within 24 hours) with the remainder undergoing hepatic methylation to monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA), which are excreted renally. Biliary and fecal elimination are minor (<5%).
Category C
Category C
Antineoplastic, PD-L1 Inhibitor
Antineoplastic, Arsenic Trioxide